NCT01209871View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 26, 2015

Primary Completion Date

February 20, 2026

Study Completion Date

February 20, 2026

Conditions
Lymphoplasmacytic Lymphoma
Interventions
BIOLOGICAL

Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine

Given ID

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER